Poolbeg Pharma upbeat on preliminary influenza drug results | News Direct

Poolbeg Pharma upbeat on preliminary influenza drug results

Poolbeg Pharma PLC
News release by Poolbeg Pharma PLC

facebook icon linkedin icon twitter icon pinterest icon email icon London, UK | January 09, 2023 09:01 AM Eastern Standard Time

Poolbeg Pharma PLC (OTCQB:POLBF) CEO Jeremy Skillington speaks to Proactive after announcing initial data analysis, including a 'clear dose-related response', for its drug, POLB 001, a potential treatment for severe influenza. Skillington says the 'early data readout' indicates that the challenge trial was successful.

Proactive Investors UK

 

 

Contact Details

 

Proactive UK Ltd

 

+44 20 7989 0813

 

uk@proactiveinvestors.com